KDCA
Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

23 August 2021

COVID-19 vaccination as of 0:00 today (cumulative since 26 February 2021) (n, %)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
Eligible	31,173,292	5,808,336	2,124,493	1,459,356	1,704,624	842,805	850,214	670,485	177,468
New (1st dose)	39,272	7,449	1,586	1,887	2,519	337	1,630	565	243
New (2nd dose)	2,241	561	209	49	103	56	73	85	1
Total (1st dose)	25,910,685	4,780,478	1,770,740	1,173,290	1,401,626	722,877	701,990	555,179	148,852
Total (2nd dose)	11,565,121	2,210,777	783,956	485,583	585,789	328,736	312,363	212,939	63,606
% (1st dose)	83.1	82.3	83.3	80.4	82.2	85.8	82.6	82.8	83.9
% (2nd dose)	37.1	38.1	36.9	33.3	34.4	39	36.7	31.8	35.8

	Province								
	Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam	Jeju
Eligible	7,548,184	1,025,829	1,004,311	1,342,390	1,171,210	1,257,750	1,719,467	2,056,431	409,939
New (1st dose)	15,535	450	1,101	1,515	876	655	1,000	1,025	899
New (2nd dose)	765	43	55	56	44	36	33	6	66
Total (1st dose)	6,311,609	850,930	843,235	1,127,066	1,000,331	1,080,873	1,417,104	1,689,427	335,078
Total (2nd dose)	2,728,328	409,030	382,135	513,477	495,112	544,675	628,772	731,381	148,462
% (1st dose)	83.6	83.0	84.0	84.0	85.4	85.9	82.4	82.2	81.7
% (2nd dose)	36.1	39.9	38	38.3	42.3	43.3	36.6	35.6	36.2

※ *Figures subject to correction recording update*

Confirmed cases by gender and age group

		New cases	(%)	Total cases	(%)	Incidence rate* (per 100,000)
Total		**1,418**	**(100)**	**237,782**	**(100)**	**459**
Sex	Male	781	(55.08)	122,134	(51.36)	473
	Female	637	(44.92)	115,648	(48.64)	445
Age	80 or above	11	(0.78)	6,662	(2.80)	332
	70-79	32	(2.26)	12,045	(5.07)	326
	60-69	110	(7.76)	28,837	(12.13)	428
	50-59	221	(15.59)	41,859	(17.60)	484
	40-49	264	(18.62)	37,738	(15.87)	455
	30-39	234	(16.50)	35,510	(14.93)	517
	20-29	321	(22.64)	43,083	(18.12)	633
	10-19	144	(10.16)	19,880	(8.36)	415
	0-9	81	(5.71)	12,168	(5.12)	306

** Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)*
※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths	(%)	Total deaths	(%)	Case fatality rate (%)	Severe/ critical	(%)
Total		**7**	**(100)**	**2,222**	**(100)**	**0.93**	**399**	**(100)**
Sex	Male	3	(42.86)	1,110	(49.95)	0.91	244	(61.15)
	Female	4	(57.14)	1,112	(50.05)	0.96	155	(38.85)
Age	80 or above	1	(14.29)	1,161	(52.25)	17.43	19	(4.76)
	70-79	2	(28.57)	619	(27.86)	5.14	48	(12.03)
	60-69	3	(42.86)	293	(13.19)	1.02	90	(22.56)
	50-59	1	(14.29)	109	(4.91)	0.26	150	(37.59)
	40-49	0	(0.00)	21	(0.95)	0.06	57	(14.29)
	30-39	0	(0.00)	11	(0.50)	0.03	27	(6.77)
	20-29	0	(0.00)	8	(0.36)	0.02	7	(1.75)
	10-19	0	(0.00)	0	(0.00)	0.00	1	(0.25)
	0-9	0	(0.00)	0	(0.00)	0.00	0	(0.00)

** Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100*
※ Figures subject to correction based on findings from epidemiological investigations

Severe/Critical Cases for past 2 weeks

	8.10.	8.11.	8.12.	8.13.	8.14.	8.15.	8.16.	8.17.	8.18.	8.19.	8.20.	8.21.	8.22.	8.23.
Total	379	387	372	369	386	374	353	354	366	390	385	403	395	399

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)

Adverse Events Following COVID-19 Vaccination

		Total (A=B+C)	Non-serious AEFI (B)	Serious AEFI (C)				Vaccinations administered (D)	% reported as AEFI (E=A/D)
				Subtotal (C=C1+C2+C3)	Death (C1)	Anaphylaxis suspected (C2)	Others (C3)		
Total	Aug 22	1,354	1,320	34	2	3	29	36,346,022	0.42
	Aug 23	569	557	12	3	0	9		
	Total	153,752	146,772	6,980	492	703	5,785		
AZ	Aug 22	315	309	6	1	0	5	14,662,441	0.56
	Aug 23	127	123	4	2	0	2		
	Total	82,273	78,460	3,813	203	290	3,320		
PF	Aug 22	756	739	17	0	2	15	18,196,516	0.31
	Aug 23	306	298	8	1	0	7		
	Total	55,559	52,872	2,687	279	342	2,066		
J	Aug 22	1	1	0	0	0	0	1,129,784	0.68
	Aug 23	0	0	0	0	0	0		
	Total	7,646	7,314	332	8	45	279		
M	Aug 22	282	271	11	1	1	9	2,357,281	0.35
	Aug 23	136	136	0	0	0	0		
	Total	8,274	8,126	148	2	26	120		

A. Based on cases reported as suspected cases of adverse events following immunization (AEFI) by healthcare institutions; Does not imply causal relationship; Report status classification subject to change if new information is added

B. Non-serious AE includes common non-serious AEFI symptoms such as redness at the injection site, pain, swelling, muscle pain, fever, headache, and chills

C. Serious AEFI includes:
Death;
Anaphylaxis suspected (including anaphylactoid reactions);
Adverse events of special interest (AESI), ICU admission, persistent or significant disability or incapacity, congenital anomaly/birth defect, life-threatened

※ Updated weekly
※ Subject to change upon new findings
※ AZ=AstraZeneca; Pf=Pfizer; J=Janssen, M=Moderna

※ Total death toll is 716 (AZ: 290, PF: 412, J: 10, M: 4) including 224 patients whose status have changed to deceased

Adverse Events Following COVID-19 Vaccination (by gender) (as of August 21 2021)

			Vaccinations administered	Total AEFI	Non-serious AEFI	Serious AEFI			
						Subtotal	Death	Anaphylaxis suspected	Others
Male	Total	Total	17,061,753	50,536	47,536	3,000	281	202	2,517
		1st dose	12,467,174	41,400	38,935	2,465	204	180	2,081
		2nd dose	4,594,579	9,136	8,601	535	77	22	436
	AZ	Total	6,820,877	24,610	23,055	1,555	120	69	1,366
		1st dose	5,121,891	23,172	21,701	1,471	109	64	1,298
		2nd dose	1,698,986	1,438	1,354	84	11	5	68
	Pf	Total	8,129,342	17,747	16,620	1,127	151	91	885
		1st dose	5,250,436	10,306	9,629	677	85	74	518
		2nd dose	2,878,906	7,441	6,991	450	66	17	367
	J	1st dose	978,890	6,087	5,824	263	8	36	219
	M	Total	1,132,644	2,092	2,037	55	2	6	47
		1st dose	1,115,957	1,835	1,781	54	2	6	46
		2nd dose	16,687	257	256	1	0	0	1
Female	Total	Total	19,237,951	102,647	98,679	3,968	208	501	3,259
		1st dose	13,399,796	82,124	78,885	3,239	139	442	2,658
		2nd dose	5,838,155	20,523	19,794	729	69	59	601
	AZ	Total	7,838,791	57,536	55,282	2,254	81	221	1,952
		1st dose	5,714,499	54,278	52,169	2,109	71	206	1,832
		2nd dose	2,124,292	3,258	3,113	145	10	15	120
	Pf	Total	10,037,514	37,506	35,954	1,552	127	251	1,174
		1st dose	6,369,883	21,240	20,265	975	68	208	699
		2nd dose	3,667,631	16,266	15,689	577	59	43	475
	J	1st dose	150,894	1,559	1,490	69	0	9	60
	M	Total	1,210,752	6,046	5,953	93	0	20	73
		1st dose	1,164,520	5,047	4,961	86	0	19	67
		2nd dose	46,232	999	992	7	0	1	6

A. Cases reported as suspected cases of adverse events following immunization (AEFI) by healthcare institutions; Does not imply causal relationship; Report status classification subject to change if new information is added

B. Includes common non-serious AEFI symptoms such as redness at the injection site, pain, swelling, muscle pain, fever, headache, and chills

C. Serious AEFI includes:
Death;
Anaphylaxis suspected (including anaphylactoid reactions);
Adverse events of special interest (AESI), ICU admission, persistent or significant disability or incapacity, congenital anomaly/birth defect, life-threatened

※ Subject to change upon new findings
※ AZ=AstraZeneca; Pf=Pfizer; J=Janssen, M=Moderna

Adverse Events Following COVID-19 Vaccination (by age) (as of August 21, 2021)

		Vaccinations administered	Total AEFI	Non-serious AEFI	Serious AEFI			
					Subtotal	Death	Anaphylaxis suspected	Others
Total	Total	36,299,704	153,183	146,215	6,968	489	703	5,776
	AZ	14,659,668	82,146	78,337	3,809	201	290	3,318
	Pf	18,166,856	55,253	52,574	2,679	278	342	2,059
	J	1,129,784	7,646	7,314	332	8	45	279
	M	2,343,396	8,138	7,990	148	2	26	120
Ages 18-29	Total	3,989,609	20,374	19,916	458	3	158	297
	AZ	271,314	5,057	4,982	75	1	29	45
	Pf	3,469,286	13,166	12,820	346	2	120	224
	J	19	0	0	0	0	0	0
	M	248,990	2,151	2,114	37	0	9	28
Ages 30-39	Total	3,023,379	19,602	18,931	671	11	152	508
	AZ	694,722	7,227	6,979	248	0	60	188
	Pf	1,421,562	6,193	6,015	178	5	54	119
	J	802,987	5,568	5,334	234	6	36	192
	M	104,108	614	603	11	0	2	9
Ages 40-49	Total	3,602,176	16,041	15,472	569	11	116	442
	AZ	1,087,039	7,591	7,269	322	9	55	258
	Pf	2,171,330	6,735	6,565	170	1	49	120
	J	197,549	1,240	1,180	60	1	6	53
	M	146,258	475	458	17	0	6	11
Ages 50-59	Total	7,492,119	20,603	19,869	734	28	115	591
	AZ	1,484,816	6,964	6,631	333	16	44	273
	Pf	4,175,139	8,844	8,536	308	10	59	239
	J	60,396	291	278	13	1	3	9
	M	1,771,768	4,504	4,424	80	1	9	70
Ages 60-69	Total	8,459,348	45,076	43,072	2,004	76	90	1,838
	AZ	7,668,251	41,692	39,797	1,895	73	83	1,739
	Pf	671,862	2,591	2,504	87	2	7	78
	J	60,234	471	450	21	0	0	21
	M	59,001	322	321	1	1	0	0
Ages 70-79	Total	6,121,989	21,752	20,302	1,450	129	32	1,289
	AZ	3,088,323	13,145	12,332	813	53	16	744
	Pf	3,012,446	8,459	7,828	631	76	16	539
	J	8,278	76	72	4	0	0	4
	M	12,942	72	70	2	0	0	2
Ages 80 and above	Total	3,611,084	9,735	8,653	1,082	231	40	811
	AZ	365,203	470	347	123	49	3	71
	Pf	3,245,231	9,265	8,306	959	182	37	740
	J	321	0	0	0	0	0	0
	M	329	0	0	0	0	0	0

A. Cases reported as suspected cases of adverse events following immunization (AEFI) by healthcare institutions; Does not imply causal relationship; Report status classification subject to change if new information is added

B. Includes common non-serious AEFI symptoms such as redness at the injection site, pain, swelling, muscle pain, fever, headache, and chills

C. Serious AEFI includes:
Death;
Anaphylaxis suspected (including anaphylactoid reactions);
Adverse events of special interest (AESI), ICU admission, persistent or significant disability or incapacity, congenital anomaly/birth defect, life-threatened

※ Subject to change upon new findings
※ AZ=AstraZeneca; Pf=Pfizer; J=Janssen, M=Moderna